

Atezolizumab**Section****Immunomodulators**

- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion
- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for

Adenocarcinoma of stomach

Hepatocellular carcinoma of liver

Therapeutic equivalent to [pembrolizumab](#) for

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of bronchus or lung

Bevacizumab**Section****Immunomodulators**

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

Hepatocellular carcinoma of liver

Blinatumomab**Section****Immunomodulators**

- Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial

Indications

B lymphoblastic leukaemia or lymphoma, not elsewhere classified

Cemiplimab**Section****Immunomodulators**

- Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for

Adenocarcinoma of stomach

Therapeutic equivalent to [pembrolizumab](#) for

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of bronchus or lung

Daratumumab

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

Indications

Plasma cell myeloma

Dostarlimab

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion

Indications

Other specified malignant neoplasms of corpus uteri

Durvalumab

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

Indications

Hepatocellular carcinoma of liver

Malignant neoplasms of biliary tract, distal bile duct

Malignant neoplasm of intrahepatic bile ducts

Malignant neoplasms of gallbladder

Malignant neoplasms of proximal biliary tract, cystic duct

Other specified malignant neoplasms of bronchus or lung

Filgrastim

Section

Immunomodulators

- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

Acquired neutropaenia

Ipilimumab

Section

Immunomodulators

- Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

Indications

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Lenalidomide

Section

Immunomodulators

- Oral > Solid: 25 mg

Indications

Plasma cell myeloma

Nivolumab

Section

Immunomodulators

- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for

Melanoma of skin

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Adenocarcinoma of oesophagogastric junction

Adenocarcinoma of stomach

Other specified malignant neoplasms of bronchus or lung

Pegfilgrastim

Section

Immunomodulators

- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

Acquired neutropaenia

Pembrolizumab

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection

Indications

Melanoma of skin

Other specified malignant neoplasms of large intestine

Malignant neoplasms of cervix uteri

Adenocarcinoma of stomach

Malignant neoplasms of oesophagogastric junction

Squamous cell carcinoma of hypopharynx and variants

Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx

Squamous cell carcinoma of oropharynx

Squamous cell carcinoma of nasopharynx

Therapeutic equivalent to nivolumab for

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Carcinoma of breast, specialised type

Squamous cell carcinoma of oesophagus

Other specified malignant neoplasms of bronchus or lung

Thalidomide

Section

Immunomodulators

- Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Tislelizumab

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 10 mL
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Indications

Malignant neoplasms of urinary tract

Squamous cell carcinoma of oesophagus

Other specified malignant neoplasms of bronchus or lung

Hodgkin lymphoma

Toripalimab

Section

Immunomodulators

- Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

Squamous cell carcinoma of oesophagus

Malignant neoplasms of nasopharynx

Tremelimumab

Section

Immunomodulators

- Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

Indications

Hepatocellular carcinoma of liver

Other specified malignant neoplasms of bronchus or lung